OncoCyte Corp. (OCX)

1.87
0.03 1.58
AMEX : Health Technology
Prev Close 1.90
Open 1.91
Day Low/High 1.81 / 1.92
52 Wk Low/High 1.10 / 6.65
Volume 56.02K
Avg Volume 51.00K
Exchange AMEX
Shares Outstanding 40.66M
Market Cap 79.29M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoCyte Files Patents For 190 Newly Identified Novel Lung Cancer Biomarkers

OncoCyte Files Patents For 190 Newly Identified Novel Lung Cancer Biomarkers

New biomarkers could assist in differentiating malignant from benign lung nodules for improved lung cancer diagnosis

OncoCyte To Present Data From Its Liquid Biopsy Breast Cancer Diagnostic Test At The San Antonio Breast Cancer Symposium

OncoCyte To Present Data From Its Liquid Biopsy Breast Cancer Diagnostic Test At The San Antonio Breast Cancer Symposium

Poster Presentation on December, 7, 2017, at 7:00 am CT

OncoCyte Becomes Oversold (OCX)

OncoCyte Becomes Oversold (OCX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OncoCyte Reports Third Quarter 2017 Financial Results

OncoCyte Reports Third Quarter 2017 Financial Results

-Conference Call Today at 4:30 pm ET-

OncoCyte Reports Positive Analytical Validation Study Results Of DetermaVu™ Lung Cancer Diagnostic Test

OncoCyte Reports Positive Analytical Validation Study Results Of DetermaVu™ Lung Cancer Diagnostic Test

DetermaVu™ Launch On-Track for Fourth Quarter 2017

OncoCyte To Present Data From Its Liquid Biopsy Breast Cancer Diagnostic Test At The San Antonio Breast Cancer Symposium

OncoCyte To Present Data From Its Liquid Biopsy Breast Cancer Diagnostic Test At The San Antonio Breast Cancer Symposium

Poster Presentation on December 7, 2017, at 7:00 am CT